Screening relatives and delaying onset
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
For most of its history, nothing could be done about type 1 diabetes before it arrived. That changed recently: the disease can be detected years early, and its onset can be delayed.
Delay is not prevention, and the honest version of this story includes both what screening offers and what it costs the person who receives the result.
Related pages: Type 1 diabetes
The bottom line
- Relatives of someone with type 1 have substantially higher risk than the general population.
- Two or more islet autoantibodies indicate early-stage disease.
- Free screening programmes exist for relatives in several countries.
- Teplizumab delays progression from stage 2 to clinical disease by a median of around two years.
- No intervention currently prevents type 1 diabetes outright.
- Whether general population screening is worthwhile.
- How long delay therapy postpones onset over longer follow-up.
- Whether combination immune therapies will achieve prevention.
The story, step by step
What the evidence labels mean
Higher, but still low
What happens
Numbers worth having.
What the research shows
- In the general population, lifetime risk of type 1 diabetes is well under 1 percent.
- A child of a mother with type 1 has a risk of roughly 2 to 3 percent; a child of a father with type 1, roughly 5 to 8 percent. The difference between maternal and paternal transmission is real and unexplained.
- A sibling has a risk of around 5 to 6 percent, higher if they share high-risk HLA types.
- An identical twin has a substantially higher risk, often quoted between 30 and 50 percent, which shows both the genetic contribution and its limits.
- Most people diagnosed have no affected relative, because the general population is so much larger than the at-risk group.
- So a family history raises risk several-fold while leaving the absolute probability modest.
Why it matters
Relatives usually overestimate their risk after a diagnosis in the family. The actual numbers are reassuring, and nobody tends to give them.
What's still uncertain
- Why paternal transmission risk exceeds maternal.
- How much HLA typing refines risk within families.
Read more
- NIH: TrialNet and type 1 diabetes prevention researchGovernment
- NIDDK: Type 1 diabetesGovernment
- American Diabetes Association: standards of care resourcesNonprofit
Next: Screening
What it involves and offers
What happens
A blood test, and a decision.
What the research shows
- Screening measures islet autoantibodies in a blood sample. Programmes exist for relatives of people with type 1 diabetes, and some are free.
- A negative result is reassuring but not permanent, so repeat testing is offered at intervals, particularly in young children.
- A single positive antibody carries modest risk. Two or more indicates early-stage disease and near-certain eventual progression.
- The practical benefits of knowing are substantial: ketoacidosis at diagnosis becomes far less likely, the family is prepared, and delay therapy and trials become options.
- The costs are real too: living with a diagnosis of something that has not yet happened, with monitoring, anxiety and possible implications for insurance.
- Screening programmes offer counselling alongside the result, because the result is not simple news.
Why it matters
The case for screening is strongest where ketoacidosis at diagnosis is common and where delay therapy is accessible. Without either, the information is harder to act on.
What's still uncertain
- Whether general population screening is cost-effective.
- How families experience a presymptomatic diagnosis over time.
Read more
- NIH: TrialNet and type 1 diabetes prevention researchGovernment
- American Diabetes Association: standards of care resourcesNonprofit
- Breakthrough T1D (formerly JDRF)Nonprofit
Next: Delaying onset
Teplizumab
What happens
The first treatment to change the course.
What the research shows
- Teplizumab is a monoclonal antibody that targets CD3 on T cells, modulating the immune attack on beta cells rather than suppressing immunity broadly.
- In a trial of relatives with stage 2 disease, a single 14-day course delayed progression to clinical diabetes by a median of around two years compared with placebo.
- It was approved in the United States in 2022 for delaying stage 3 type 1 diabetes in people aged 8 and over with stage 2 disease.
- Side effects include a temporary fall in lymphocyte counts, rash and, less often, a reaction in the first days of treatment, so it is given with monitoring.
- It delays rather than prevents. Most people treated still develop clinical diabetes eventually.
- Access depends on having been screened in the first place, which is the main practical barrier.
Why it matters
Two years of additional insulin-free life, particularly for a child, is a substantial gain, and it is the first time anything has altered the trajectory at all.
What's still uncertain
- How long the delay persists with longer follow-up.
- Whether repeated courses extend the benefit.
Read more
- FDA: drug and device informationGovernment
- NIH: TrialNet and type 1 diabetes prevention researchGovernment
- American Diabetes Association: standards of care resourcesNonprofit
Next: Primary prevention
The honest answer
What happens
Not yet.
What the research shows
- Nothing currently prevents type 1 diabetes from starting. No diet, supplement, vaccine or lifestyle change has been shown to do so.
- Trials have tested oral and nasal insulin to induce tolerance, nicotinamide, vitamin D, omega-3 fatty acids, hydrolysed infant formula and gluten-free diets in infancy. None prevented the disease.
- Breastfeeding and avoiding early cow's milk exposure have been studied extensively, and the large randomised trial did not find a protective effect.
- Research continues on antigen-specific immunotherapy, combination immune treatments, and beta-cell protection, and these are now tested at earlier stages.
- Beta-cell replacement, including stem-cell-derived islet transplantation, has produced insulin independence in early trials and remains limited by the need for immunosuppression.
- Claims that type 1 diabetes can be prevented or reversed by diet or supplements are not supported, and they do active harm when they lead to delayed or reduced insulin.
Why it matters
The absence of primary prevention is not a gap in effort. It is the direct consequence of not knowing what triggers the process.
What's still uncertain
- Whether any intervention will eventually prevent onset.
- Whether stem-cell-derived islets can work without immunosuppression.
Read more
- NIH: TrialNet and type 1 diabetes prevention researchGovernment
- NIDDK: Type 1 diabetesGovernment
- Breakthrough T1D (formerly JDRF)Nonprofit